More specifically, CT26 cells show statistically significant reductions in tumor volumes in response to murine anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) treatment and anti-PD-1 treatment [18]. This evidence concerns the gene PDCD1 and neoplasm.